Monitor the trial schedule and any related district-court or ITC litigation that may be stayed or affected. The final written decision will determine whether claims are cancelled, which could impact Neurocrine's competitive position if the patent covers a product or therapy relevant to its pipeline.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $169.14entry
- T+1 · 6d ago +3.12%α +1.80% · $174.41
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outExecutive Summary
The PTAB granted institution of post-grant review (PGR2026-00061) on Neurocrine's petition challenging claims of Spruce Biosciences' patent covering methods for treating testicular and ovarian adrenal rest tumors. This is an interlocutory ruling that opens a trial; no claims have been cancelled yet.
PTAB Trial Details
Key Facts
- PTAB instituted PGR2026-00061 on November 10, 2026
- Patent U.S. 12576084 covers methods for treating testicular and ovarian adrenal rest tumors
- Neurocrine Biosciences is the petitioner; Spruce Biosciences is the patent owner
- Institution granted means the Board found it more likely than not that at least one challenged claim is unpatentable
- This is an interlocutory decision; a final written decision is expected within approximately one year
Financial Impact
Not quantifiable from the decision; the patent's materiality to Neurocrine's business is not stated
Risk Factors
- Institution is interlocutory; no claims have been invalidated
- The patent's connection to Neurocrine's products or revenue is not stated in the decision
- Outcome uncertain until final written decision, which may be appealed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-PGR2026-00061-ins-NBIX |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Viewing Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers